MedTrace Logo

Escitalopram for Agitation in Alzheimer's Disease

NCT03108846 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2025-01-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.

Conditions

Interventions

DRUG

Escitalopram

5-15 mg/day (target: 15mg/day if tolerated)

DRUG

Placebo

Masked placebo

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • JHSPH Center for Clinical Trials

    lead OTHER

Principal Investigators

  • Constantine Lyketsos, MD, MHS · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
109 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-03
Primary Completion
2024-04-05
Completion
2025-05-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108846 on ClinicalTrials.gov